Ionis Pharmaceuticals (0JDI) Share Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0JDI Analyst Ratings

Strong Buy

16 Buy

4 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Ionis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0JDI Stock 12 Month Forecast

Average Price Target

$85.33

▲(41.77% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $85.33 with a high forecast of $104.00 and a low forecast of $54.00. The average price target represents a 41.77% change from the last price of $60.19.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"41":"$41","57":"$57","73":"$73","89":"$89","105":"$105"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$104.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85.33333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$85.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[41,57,73,89,105],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.35,63.70769230769231,67.06538461538462,70.42307692307692,73.78076923076924,77.13846153846154,80.49615384615385,83.85384615384615,87.21153846153847,90.56923076923077,93.92692307692309,97.28461538461539,100.6423076923077,{"y":104,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.35,62.271794871794874,64.19358974358974,66.11538461538461,68.03717948717949,69.95897435897436,71.88076923076923,73.8025641025641,75.72435897435898,77.64615384615385,79.56794871794872,81.48974358974358,83.41153846153846,{"y":85.33333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.35,59.861538461538466,59.37307692307692,58.88461538461539,58.396153846153844,57.90769230769231,57.41923076923077,56.93076923076923,56.44230769230769,55.95384615384616,55.465384615384615,54.97692307692308,54.488461538461536,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.215,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.499,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.93,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.94,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.77,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.604,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.15,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.73,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.35,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$104.00

Average Price Target$85.33

Lowest Price Target$54.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yaron Werber

TD Cowen

$94→$84

Buy

39.56%

Upside

Reiterated

09/08/26

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), PMV Pharmaceuticals (NASDAQ: PMVP) and Tyra Bioscience (NASDAQ: TYRA)

Joseph Stringer

Needham

$86

Buy

42.88%

Upside

Reiterated

09/08/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Ionis Pharmaceuticals (NASDAQ: IONS)

Salveen Richter

Goldman Sachs

$69→$56

Hold

-6.96%

Downside

Assigned

09/08/26

Ionis Pharmaceuticals price target lowered to $56 from $69 at Goldman SachsIonis Pharmaceuticals price target lowered to $56 from $69 at Goldman Sachs

Mitchell Kapoor

H.C. Wainwright

$115→$100

Buy

66.14%

Upside

Reiterated

09/08/26

Ionis Pharmaceuticals price target lowered to $100 from $115 at H.C. WainwrightIonis Pharmaceuticals price target lowered to $100 from $115 at H.C. Wainwright

Michael Ulz

Morgan Stanley

$110→$104

Buy

72.79%

Upside

Reiterated

09/08/26

Ionis Pharmaceuticals (IONS) Gets a Buy from Morgan Stanley

Gary Nachman

Canaccord Genuity

$95→$85

Buy

41.22%

Upside

Reiterated

09/08/26

Canaccord Genuity Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

David Lebowitz

Citi

$61→$54

Hold

-10.28%

Downside

Reiterated

09/08/26

Ionis Pharmaceuticals price target lowered to $54 from $61 at BMO CapitalIonis Pharmaceuticals price target lowered to $54 from $61 at BMO Capital

Myles Minter

William Blair

―

Buy

―

Reiterated

09/04/26

Ionis Pharmaceuticals: Buy Rating Backed by FDA Approval of Zanvastro and Strengthened Neurology Pipeline Upside

Eric Joseph

Citi

$100

Buy

66.14%

Upside

Reiterated

09/04/26

Ionis Buy Rating Reiterated as Analyst Sees Limited Impact from Lp(a)HORIZON Setback and Maintains $100 Price Target

Eliana Merle

Barclays

$90

Buy

49.53%

Upside

Reiterated

09/01/26

Barclays Remains a Buy on Ionis Pharmaceuticals (IONS)

Jason Gerberry

Bank of America Securities

$83→$93

Buy

54.51%

Upside

Reiterated

08/31/26

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS)

Allison Bratzel

Piper Sandler

$94

Buy

56.17%

Upside

Reiterated

08/17/26

Ionis Pharmaceuticals (IONS) Receives a Buy from Piper Sandler

Yanan Zhu

Wells Fargo

$95

Buy

57.83%

Upside

Reiterated

08/14/26

Ionis Pharmaceuticals (IONS) Receives a Buy from Wells Fargo

Jessica Fye

J.P. Morgan

$76

Buy

26.27%

Upside

Assigned

08/10/26

J.P. Morgan Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

Paul Matteis

Stifel Nicolaus

$86→$68

Hold

12.98%

Upside

Reiterated

08/02/26

Ionis Pharmaceuticals (IONS) Receives a Hold from Stifel Nicolaus

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yaron Werber

TD Cowen

$94→$84

Buy

39.56%

Upside

Reiterated

09/08/26

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), PMV Pharmaceuticals (NASDAQ: PMVP) and Tyra Bioscience (NASDAQ: TYRA)

Joseph Stringer

Needham

$86

Buy

42.88%

Upside

Reiterated

09/08/26

Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (NASDAQ: DYN), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Ionis Pharmaceuticals (NASDAQ: IONS)

Salveen Richter

Goldman Sachs

$69→$56

Hold

-6.96%

Downside

Assigned

09/08/26

Ionis Pharmaceuticals price target lowered to $56 from $69 at Goldman SachsIonis Pharmaceuticals price target lowered to $56 from $69 at Goldman Sachs

Mitchell Kapoor

H.C. Wainwright

$115→$100

Buy

66.14%

Upside

Reiterated

09/08/26

Ionis Pharmaceuticals price target lowered to $100 from $115 at H.C. WainwrightIonis Pharmaceuticals price target lowered to $100 from $115 at H.C. Wainwright

Michael Ulz

Morgan Stanley

$110→$104

Buy

72.79%

Upside

Reiterated

09/08/26

Ionis Pharmaceuticals (IONS) Gets a Buy from Morgan Stanley

Gary Nachman

Canaccord Genuity

$95→$85

Buy

41.22%

Upside

Reiterated

09/08/26

Canaccord Genuity Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

David Lebowitz

Citi

$61→$54

Hold

-10.28%

Downside

Reiterated

09/08/26

Ionis Pharmaceuticals price target lowered to $54 from $61 at BMO CapitalIonis Pharmaceuticals price target lowered to $54 from $61 at BMO Capital

Myles Minter

William Blair

―

Buy

―

Reiterated

09/04/26

Ionis Pharmaceuticals: Buy Rating Backed by FDA Approval of Zanvastro and Strengthened Neurology Pipeline Upside

Eric Joseph

Citi

$100

Buy

66.14%

Upside

Reiterated

09/04/26

Ionis Buy Rating Reiterated as Analyst Sees Limited Impact from Lp(a)HORIZON Setback and Maintains $100 Price Target

Eliana Merle

Barclays

$90

Buy

49.53%

Upside

Reiterated

09/01/26

Barclays Remains a Buy on Ionis Pharmaceuticals (IONS)

Jason Gerberry

Bank of America Securities

$83→$93

Buy

54.51%

Upside

Reiterated

08/31/26

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS)

Allison Bratzel

Piper Sandler

$94

Buy

56.17%

Upside

Reiterated

08/17/26

Ionis Pharmaceuticals (IONS) Receives a Buy from Piper Sandler

Yanan Zhu

Wells Fargo

$95

Buy

57.83%

Upside

Reiterated

08/14/26

Ionis Pharmaceuticals (IONS) Receives a Buy from Wells Fargo

Jessica Fye

J.P. Morgan

$76

Buy

26.27%

Upside

Assigned

08/10/26

J.P. Morgan Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

Paul Matteis

Stifel Nicolaus

$86→$68

Hold

12.98%

Upside

Reiterated

08/02/26

Ionis Pharmaceuticals (IONS) Receives a Hold from Stifel Nicolaus

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ONCBeOne Medicines

DNLIDenali Therapeutics

SNDXSyndax Pharmaceuticals

ZYMEZymeworks

PTGXProtagonist Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ionis Pharmaceuticals

3 Months

Mitchell KapoorH.C. Wainwright

Success Rate

11/17 ratings generated profit

Average Return

+21.86%

Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +21.86% per trade.

1 Year

Gary NachmanCanaccord Genuity

Success Rate

16/27 ratings generated profit

Average Return

+23.10%

Copying Gary Nachman's trades and holding each position for 1 Year would result in 59.26% of your transactions generating a profit, with an average return of +23.10% per trade.

2 Years

Yanan ZhuWells Fargo

Success Rate

23/29 ratings generated profit

Average Return

+35.74%

Copying Yanan Zhu's trades and holding each position for 2 Years would result in 79.31% of your transactions generating a profit, with an average return of +35.74% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0JDI Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0JDI has received 58 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. 0JDI average Analyst price target in the past 3 months is 85.33.

Each month's total comprises the sum of three months' worth of ratings.

0JDI Financial Forecast

0JDI Earnings Forecast

Next quarter’s earnings estimate for 0JDI is -$1.21 with a range of -$1.42 to -$0.96. The previous quarter’s EPS was -$0.69. 0JDI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0JDI has Performed in-line its overall industry.

0JDI Sales Forecast

Next quarter’s sales forecast for 0JDI is $181.79M with a range of $151.86M to $225.00M. The previous quarter’s sales results were $267.95M. 0JDI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0JDI has Performed in-line its overall industry.

0JDI Stock Forecast FAQ

What is GB:0JDI’s average 12-month price target, according to analysts?

Based on analyst ratings, Ionis Pharmaceuticals’s 12-month average price target is 85.33.

What is GB:0JDI’s upside potential, based on the analysts’ average price target?

Ionis Pharmaceuticals has 41.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Ionis Pharmaceuticals a Buy, Sell or Hold?

Ionis Pharmaceuticals has a consensus rating of Strong Buy, which is based on 16 buy ratings, 4 hold ratings and 0 sell ratings.

What is Ionis Pharmaceuticals’s share price target?

The average share price target for Ionis Pharmaceuticals is 85.33. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $104.00 ,and the lowest forecast is $54.00. The average share price target represents 41.77% Increase from the current price of $60.19.

What do analysts say about Ionis Pharmaceuticals?

Ionis Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Ionis Pharmaceuticals?

To buy shares of GB:0JDI, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Ionis Pharmaceuticals (0JDI) Share Forecast & Price Target

0JDI Analyst Ratings

0JDI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ionis Pharmaceuticals

0JDI Analyst Recommendation Trends

0JDI Financial Forecast

0JDI Earnings Forecast

0JDI Sales Forecast

0JDI Stock Forecast FAQ

Detailed List of Analyst Forecasts